Kura Oncology (KURA) Misses Q4 EPS by 66c

Kura Oncology (NASDAQ: KURA) reported Q4 EPS of ($0.92), $0.66 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $17.34 million versus the consensus estimate of $74.52 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Tapestry Inc. (TPR) PT Raised to $230 at UBS on Long-Term Growth Potential
• Rentokil Terminix rolls out digital pest control upgrades across brands